BIOMAT Database Logo BIOMAT Database Logo

Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms. 2004

M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
Department of Psychiatry, University of Mainz, Mainz, Germany. mjm@mail.psychiatrie.klinik.uni-mainz.de

BACKGROUND It is well known that sleep disturbance is an integral symptom of schizophrenia. In recent studies, a deficit of delta sleep has been observed in schizophrenic patients. Antipsychotic drugs with serotonin (5-HT2) receptor-antagonistic properties are considered to have delta sleep promoting effects. We have investigated the effects of subchronic olanzapine treatment on sleep EEG in schizophrenic patients. METHODS The effects of administration of olanzapine (15 to 20 mg) on sleep were studied for four weeks in 10 male, drug-free patients suffering from schizophrenia with predominantly negative symptoms. Conventional sleep EEG parameters were investigated at baseline and after treatment with olanzapine for four weeks. Additionally, spectral power analysis of the EEG signal in distinct frequency bands was computed for different sleep stages. Psychopathology (PANSS, HAMD-17, HAMA) and side effects were assessed weekly. RESULTS All patients improved, as measured by PANSS global scores. Compared to baseline, there was a significant improvement of parameters of sleep efficiency and an increase of delta sleep as well as REM sleep. Regarding spectral power values, no significant differences between baseline and treatment conditions were found. CONCLUSIONS Sleep improvement was due to parameters of sleep efficiency and delta sleep, which may be related to serotonin antagonistic properties of olanzapine.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D003700 Delta Rhythm Brain waves seen on EEG characterized by a high amplitude and a frequency of 4 Hz and below. They are considered the "deep sleep waves" observed during sleep in dreamless states, infancy, and in some brain disorders. Delta Rhythms,Rhythm, Delta,Rhythms, Delta
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077152 Olanzapine A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy. 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine,LY 170053,LY-170052,Olanzapine Pamoate,Zolafren,Zyprexa,LY 170052,LY170052
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
Negative symptoms and EEG alpha activity in schizophrenic patients.
October 1992, Schizophrenia research,
M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
[Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
September 1991, Fortschritte der Neurologie-Psychiatrie,
M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: an open prospective pilot study.
July 1999, International clinical psychopharmacology,
M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
[SSRI antidepressants and negative schizophrenic symptoms: differences between paroxetine and fluvoxamine in patients treated with olanzapine].
January 2009, Rivista di psichiatria,
M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
May 2000, International clinical psychopharmacology,
M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
September 2007, European archives of psychiatry and clinical neuroscience,
M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
Dissociative symptoms in schizophrenic patients with positive and negative symptoms.
January 1997, Psychopathology,
M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency.
July 1999, Biological psychiatry,
M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
EEG sleep patterns in schizophrenic patients undergoing hemodialysis.
December 1981, Psychiatry research,
M J Müller, and W Rossbach, and K Mann, and J Röschke, and F Müller-Siecheneder, and M Blümler, and H Wetzel, and H Russ, and R W Dittmann, and O Benkert
A quantitative sleep-EEG study on the effects of benzodiazepine and zopiclone in schizophrenic patients.
May 1995, Schizophrenia research,
Copied contents to your clipboard!